for treatment efficacy (g=1.52 vs. 1.41), treatment response (RR=5.50 vs. 3.67), or symptom diagnostic/remission (RR=6.69 vs. 4.47). There were no other significant moderators of treatment efficacy, treatment response, or symptom/diagnostic remission among non-active comparison trials. Table 3 also presents moderator analyses for active-comparison trials across all three outcome types. For treatment efficacy, a positive association was found between comorbid TS/CTD and ES, with trials that had a greater percentage of TS/CTD exhibited larger ES. Otherwise, there were no significant moderators of treatment efficacy, treatment response, or symptom/diagnostic remission among active-comparison trials.
